Annexon Inc Overview
Pro stress-test →Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company is focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases.
Strategic Profile
Pro stress-test →Annexon's platform technology addresses classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, advancing a portfolio of product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). ANX005 is in Phase 3 clinical trial for guillain-barré syndrome and Phase 2a for amyotrophic lateral sclerosis, while ANX007 is in Phase 3 for geographic atrophy treatment.
Competitive Landscape
Pro stress-test →Competitors in the complement/neurodegenerative space include Alector, Sorrento Therapeutics, Vedanta Biosciences, Alzheon, and CRISPR Therapeutics. Annexon's C1q-focused mechanism provides differentiation versus broader complement inhibitors. As a clinical-stage player, it competes against both established pharma programs and other biotech developers targeting similar disease areas.
Industry Context
Annexon Inc operates in Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases.
Key facts
Founded: 2011 · Headquarters: Brisbane, California, US · Employees: 117 · Market cap: $759M